Abstract 412P
Background
To study of cytogenetic changes in peripheral blood lymphocytes of patients with osteosarcoma.
Methods
Studies were conducted in peripheral blood samples of 196 patients with osteosarcoma (OS) aged from 10 to 45 years. The primary cytogenetic study of patients was carried out before their clinical examination.
Results
The analysis showed that after chemotherapy, 59.5% of patients had a full and partial effect. At 46.2%, the background level of chromosomal abnormalities was less than 5% (discriminatory or dividing level), but 2.5 times higher than the average level of chromosomal abnormalities in healthy individuals. The lack of effect was observed in 40.5% of patients, and their background chromosomal abnormalities were higher than discriminatory (5%) and 7.5 times higher than in healthy individuals. A comparative analysis of the effectiveness of the treatment and the average background level of Cr-disorders among patients in this group showed that 46.2% of patients with a positive effect from chemotherapy had an average level of Cr-disorders in peripheral blood lymphocytes 2.4 times lower, than in patients with a lack of effect from this therapy.
Conclusions
The analysis showed that in the absence of the effect of the treatment carried out, the background indicators of chromosomal aberrations are significantly higher than in healthy individuals or in individuals with good clinical effect. Consequently, according to the level of chromosome aberrations in the peripheral blood lymphocytes of patients with OS identified before the start of treatment, the therapeutic effect can be predicted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ronc.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract